1
Zeppezauer Michael, Reichhart Robert: Pure histone h1 for use in therapeutic procedures.. Symbiotec, October 17, 1990: EP0392315-A1 (5 worldwide citation)

The invention relates to the use of pure histones H1, or the histone dimer H2A:H2B for therapeutic procedures. Instead of the pure histones active segments thereof with hormone or hormone like activity especially thymic hormone like activity can be used alone or in combination with the pure histones ...


2
Michael Zeppezauer, Hans P Leinenbach: Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures. Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie mbH, Kanesaka & Takeuchi, November 26, 1996: US05578571 (4 worldwide citation)

According to this invention the combination of active substances for use in therapeutic procedures consists of at least one cytostatic compound, e.g. vincristine, methotrexate, cisplatin as the first agent and at least one histone and/or one active histone fragment with cytostatic or cytotoxic activ ...


3
Reiner Class, Michael Zeppezauer: Antimicrobial histone H1 compositions, kits, and methods of use thereof. Symbiotec, Philadelphia Health and Education Corporation, Akin Gump Strauss Hauer & Feld, April 26, 2005: US06884423 (3 worldwide citation)

The invention includes antibiotic pharmaceutical compositions comprising eukaryotic histone H1 protein and methods of using eukaryotic histone H1 protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a euk ...


4
Peter Gross, Hans Jornvall, Grazyna Formicka Zeppezauer, Michael Zeppezauer, Michel Thiry: Bis-met histones. Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie mbH, One3 IP Management P C, Annette S Parent, Dean G Stathakis, August 9, 2016: US09409960 (2 worldwide citation)

The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing s ...


5
Zeppezauer Michael Prof Dr, Leinenbach Hans Peter Dr: Cytostatic or cytotoxic combination of active subtances for use in therapeutic procedures.. Symbiotec, July 31, 1991: EP0438756-A1 (1 worldwide citation)

The combination of agents according to the invention for use in therapeutic procedures, in particular for the treatment of cancers or autoimmune diseases, consists of at least one cytostatic (e.g. vincristine, methotrexate, cisplatin) as a first agent and of at least one histone and/or at least one ...


6
Michael Zeppezauer, Arno Schönberger, Ladislav Cebecauer: Peptides for the production of preparations for the diagnosis and therapy of systemic lupus. Symbiotec Gesellschaft zur Erforschung und Entwicklung auf dem Gebiet der Biotechnologic mbH, Eugene C Raucidlo, Greenburg Traurig, April 9, 2002: US06369203 (1 worldwide citation)

Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from systemic lupus erythematosus (SLE). In the case of the peptides it is preferably a question of the C terminus of H1 with the sequence section 187- ...


7
Zeppezauer Michael Prof Dr, Schoenberger Arno Dr, Cebecauer Ladislav Dr: Peptides for the preparation of means for diagnosis and therapy of systemic lupus.. Symbiotec, March 24, 1993: EP0532979-A2 (1 worldwide citation)

Peptides having antigenic or immunogenic determinants are proposed which are recognised by autoantibodies, in particular in body fluids of patients who suffer from systemic lupus erythematosus (SLE). The two peptides are preferably the C-terminus of H1 containing the sequence section 187 - 211 and t ...


8
Class Reiner Dr Ph D: Use of histones for the early diagnosis and/or preventive therapy of virus-infected living cells and a biochip for implementation of the diagnosis. Symbiotec, Philadelphia Health &Amp, Educatio, November 9, 2005: EP1593385-A1

Biologically active substance (I), preferably for early diagnosis and/or preventive therapy of virus-infected living cells, comprises at least one component of histone, covalent modified histone, similar histone polypeptide, biologically active sequences of the histone and similar histone peptide. - ...


9
Michael Zeppezauer, Peter Gross: Use of an active biological substance in abnormal cellular and viral membrane physiologies. Symbiotec Gesellschaft zur Forshung und Entwickling auf dem Gebiet der Biotechnologie mbH, One3 IP Management PC, Dean G Stathakis, Peter D Weinstein, July 15, 2014: US08778875

An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including ...


10
Bis-met histones. Symbiotec, Thiry Michel, October 29, 2008: EP1985628-A1

The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing s ...



Click the thumbnails below to visualize the patent trend.